SCHEMBL3179017

SCHEMBL3179017

CCOC(=O)C(C(=O)OCC)=C1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
ALDH1A1 P00352 8/20 0.38
NPSR1 Q6W5P4 1/20 0.36
GLO1 Q04760 1/20 0.36
LMNA P02545 3/20 0.36
HSD17B10 Q99714 2/20 0.36
GAA P10253 2/20 0.36
ALOX15 P16050 2/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
TSHR P16473 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
GLA P06280 1/20 0.35
MGAM O43451 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3200633 0.98 MAPT (0.39) MAPTALDH1A1NPSR1GLO1LMNA
SCHEMBL13269286 0.96 ALDH1A1 (0.39) MAPTALDH1A1NPSR1GLO1LMNA
SCHEMBL450892 0.94 MAPT (0.39) MAPTALDH1A1NPSR1GLO1LMNA
SCHEMBL13269472 0.94 ALDH1A1 (0.41) MAPTALDH1A1NPSR1GLO1LMNA
SCHEMBL6356446 0.90 GRIK1 (0.39) MAPTALDH1A1NPSR1GLO1HSD17B10
SCHEMBL14899076 0.90 MAPT (0.45) MAPTALDH1A1NPSR1GLO1LMNA
SCHEMBL2045397 0.89 ALDH1A1 (0.42) MAPTALDH1A1NPSR1GLO1LMNA
SCHEMBL14899078 0.88 MAPT (0.46) MAPTALDH1A1NPSR1GLO1LMNA
SCHEMBL20262430 0.84 ALDH1A1 (0.36) MAPTALDH1A1LMNAGAAKDM4E
SCHEMBL15492519 0.82 FAAH (0.51) MAPTALDH1A1NPSR1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10308563-B2 Process for producing ethylene oligomers HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) 2019-06-04 US disclosed
US-20180169642-A1 CATALYST SYSTEM FOR ETHYLENE OLIGOMERIZATION AND METHOD FOR PRODUCING ETHYLENE OLIGOMERIZATION USING THE SAME HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) 2018-06-21 US disclosed
US-20180170827-A1 PROCESS FOR PRODUCING ETHYLENE OLIGOMERS HANWHA TOTALENERGIES PETROCHEMICAL CO., LTD. (KR) 2018-06-21 US disclosed
EP-2995615-A1 CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR PHARMACEUTICAL USE AstraZeneca AB (SE) 2016-03-16 EP disclosed
EP-2272825-B1 Protected amino hydroxy adamantane carboxylic acid and process for its preparation ASTRAZENECA AB (SE) 2015-11-04 EP disclosed
US-RE44186-E1 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-30 US disclosed
EP-2272825-A2 N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation Bristol-Myers Squibb Company (US) 2011-01-12 EP disclosed
US-RE41149-E1 Stereoisomerically pure 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid or a pharmaceutically acceptable salt thereof; antibacterial agents DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-23 US disclosed
US-7632953-B2 Process for the preparation of gabalactam HIKAL LIMITED (IN) 2009-12-15 US disclosed
EP-1599446-B1 AN IMPROVED PROCESS FOR THE PREPARATION OF GABALACTAM HIKAL LTD (IN) 2009-08-12 EP disclosed
US-5508428-A Spiro compound DAIICHI PHAMACEUTICAL CO., LTD. (JP) 1996-04-16 US disclosed
US-5286723-A Spiro compound DAIICHI SEIYAKU CO., LTD. 1994-02-15 US disclosed
EP-0357047-B1 Spiro compounds DAIICHI SEIYAKU CO (JP) 1993-11-03 EP disclosed
EP-0529688-A2 Azaspiro n,m alkanes and diazaspiro n,m -alkanes DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1993-03-03 EP disclosed
US-5151497-A Central nervous system disorders, antidepressants, epilepsy and cognition activators JAPAN TOBACCO INC. (JP) 1992-09-29 US disclosed
EP-0358092-B1 2-AZA-4-(ALKOXYCARBONYL)SPIRO-(4,5)DECAN-3-ONE LONZA A.G. (CH) 1991-12-11 EP disclosed
US-4958044-A 2-aza-4-(alkoxycarbonyl)spiro[4,5]-decan-3-one LONZA LTD. (CH) 1990-09-18 US disclosed
US-4956473-A ANTICONVULSANTS LONZA LTD. (CH) 1990-09-11 US disclosed
EP-0384380-A2 Novel peptide derivatives and their pharmaceutical use JAPAN TOBACCO INC. (JP) 1990-08-29 EP disclosed
EP-0357047-A1 Spiro compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1990-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10308563-B2 Process for producing ethylene oligomers OXER1, HAO2, ORC3 MAPT 2725/4885ALDH1A1 1507/4885NPSR1 2694/4885
US-20180169642-A1 CATALYST SYSTEM FOR ETHYLENE OLIGOMERIZATION AND METHOD FOR PRODUCING ETHYLENE OLIGOMERIZATION USING THE SAME HACL2, HAO2, MSMO1 MAPT 3710/4885ALDH1A1 1614/4885NPSR1 2922/4885
US-20180170827-A1 PROCESS FOR PRODUCING ETHYLENE OLIGOMERS OXER1, HAO2, ORC3 MAPT 2725/4885ALDH1A1 1507/4885NPSR1 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.